{
  "id": 3934,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Debate / Critical Discussion"
    },
    "dialogue_turns": [
      {
        "speaker": "HostA",
        "text": "Carl Hansen's company, AbCellera, just had a $480 million valuation, but their COVID-19 treatment failed spectacularly. I'm not convinced this \"drug distribution as a service\" model is viable.",
        "tts_text": "Carl Hansen's company, AbCellera, just had a four hundred eighty dollars million valuation, but their COVIDminus nineteen treatment failed spectacularly. I'm not convinced this drug distribution as a service model is viable.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "But AbCellera, which raised $105 million from investors including Peter Thiel, the Universityof Minnesota and OrbiMed in Mayat a valuation of $4.8 billion, according to PitchBook, just six months before going publicis not interested in seeing it through from beginning to end. Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Well, but you have to consider the context—they're working with giants like Astrazeneca and Gilead. Their approach is about speeding up discovery, not necessarily guaranteeing every drug succeeds.",
        "tts_text": "Well, but you have to consider the context-they're working with giants like Astrazeneca and Gilead. Their approach is about speeding up discovery, not necessarily guaranteeing every drug succeeds.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Speeding up? The bamlanivimab antibody never even made it to clinical trials, and the FDA denied emergency use. That doesn't sound efficient.",
        "tts_text": "Speeding up? The bamlanivimab antibody never even made it to clinical trials, and the F D A denied emergency use. That doesn't sound efficient.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started. Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "True, but um, antibody treatments are inherently risky—Hansen himself said fewer than 99% of new drugs make it. The fact that they identified candidates so quickly is still impressive.",
        "tts_text": "True, but um, antibody treatments are inherently risky-Hansen himself said fewer than ninety nine percent of new drugs make it. The fact that they identified candidates so quickly is still impressive.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Its not a sure thingfewer than 10% of new drugs make it all the way.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Impressive? They earned zero royalties from it, according to Credit Suisse. And Eli Lilly expected millions in revenue that just vanished.",
        "tts_text": "Impressive? They earned zero royalties from it, according to Credit Suisse. And Eli Lilly expected millions in revenue that just vanished.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Eli Lilly issued guidance in mid-December expecting up to $2 billion in revenue from Covid-19 therapeutics in 2021, the bulk of which will come from bamlanivimab; AbCellera, which booked $25 million through the end of September 2020, will earn estimated royalties of $270 million on those sales, according to Credit Suisse.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Yeah, but look at their broader strategy—they're not trying to be a traditional pharma company. They focus on the distribution process, which is where most bottlenecks happen.",
        "tts_text": "Yeah, but look at their broader strategy-they're not trying to be a traditional pharma company. They focus on the distribution process, which is where most bottlenecks happen.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Instead of trying to build a vertically integrated drug company, it is focused solely on the discovery process.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Bottlenecks or not, investors like Bill Gates put money expecting returns. Delays cost millions in opportunity, like that Goldman Sachs analyst mentioned.",
        "tts_text": "Bottlenecks or not, investors like Bill Gates put money expecting returns. Delays cost millions in opportunity, like that Goldman Sachs analyst mentioned.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "But AbCellera, which raised $105 million from investors including Peter Thiel, the Universityof Minnesota and OrbiMed in Mayat a valuation of $4.8 billion, according to PitchBook, just six months before going publicis not interested in seeing it through from beginning to end. From a financial perspective, every year that you save is a huge opportunity cost for investors, says Gal Munda, an analyst at Berenberg Capital Markets.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "I get the skepticism, but AbCellera's tech is unproven, not useless. Hansen came from academia—he knows discovery is messy. Even their failure with COVID antibodies might refine their methods.",
        "tts_text": "I get the skepticism, but AbCellera's tech is unproven, not useless. Hansen came from academia-he knows discovery is messy. Even their failure with COVID antibodies might refine their methods.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Messy\" is an understatement. They examined antibodies from people who hadn't recovered—that feels counterintuitive, almost like they were set up to fail.",
        "tts_text": "Messy is an understatement. They examined antibodies from people who hadn't recovered-that feels counterintuitive, almost like they were set up to fail.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Or maybe it's about learning what doesn't work faster. Their IPO was white-hot; Hansen's now a millionaire. The market clearly sees potential here.",
        "tts_text": "Or maybe it's about learning what doesn't work faster. Their I P O was white-hot; Hansen's now a millionaire. The market clearly sees potential here.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Potential doesn't pay bills if your flagship projects collapse. I'll need to see more than one professor-turned-CEO's optimism.",
        "tts_text": "Potential doesn't pay bills if your flagship projects collapse. I'll need to see more than one professor-turned-C E O's optimism.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Fair enough, but remember, seven of the top ten drugs in 2018 were antibody treatments. The field is booming, and AbCellera's niche could still pay off.",
        "tts_text": "Fair enough, but remember, seven of the top ten drugs in twenty eighteen were antibody treatments. The field is booming, and AbCellera's niche could still pay off.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Seven of the 10 top-selling drugs in 2018 were antibody treatments, including AbbVies $19 billion (net revenue) immunosuppressive drug Humira and Mercks cancer drug Keytruda, which generated $11.1 billion in 2019.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "We'll see. For now, I'm keeping my expectations low.",
        "tts_text": "We'll see. For now, I'm keeping my expectations low.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": "",
        "confidence": 1.0
      }
    ]
  },
  "generator_model": "DeepSeek-V3.1",
  "batch_index": 2,
  "artist_script": "HostA: Carl Hansen's company, AbCellera, just had a $480 million valuation, but their COVID-19 treatment failed spectacularly. I'm not convinced this \"drug distribution as a service\" model is viable.\nHostB: Well, but you have to consider the context—they’re working with giants like Astrazeneca and Gilead. Their approach is about speeding up discovery, not necessarily guaranteeing every drug succeeds.\nHostA: Speeding up? The bamlanivimab antibody never even made it to clinical trials, and the FDA denied emergency use. That doesn’t sound efficient.\nHostB: True, but um, antibody treatments are inherently risky—Hansen himself said fewer than 99% of new drugs make it. The fact that they identified candidates so quickly is still impressive.\nHostA: Impressive? They earned zero royalties from it, according to Credit Suisse. And Eli Lilly expected millions in revenue that just vanished.\nHostB: Yeah, but look at their broader strategy—they’re not trying to be a traditional pharma company. They focus on the distribution process, which is where most bottlenecks happen.\nHostA: Bottlenecks or not, investors like Bill Gates put money expecting returns. Delays cost millions in opportunity, like that Goldman Sachs analyst mentioned.\nHostB: I get the skepticism, but AbCellera’s tech is unproven, not useless. Hansen came from academia—he knows discovery is messy. Even their failure with COVID antibodies might refine their methods.\nHostA: Messy\" is an understatement. They examined antibodies from people who hadn’t recovered—that feels counterintuitive, almost like they were set up to fail.\nHostB: Or maybe it’s about learning what doesn’t work faster. Their IPO was white-hot; Hansen’s now a millionaire. The market clearly sees potential here.\nHostA: Potential doesn’t pay bills if your flagship projects collapse. I’ll need to see more than one professor-turned-CEO’s optimism.\nHostB: Fair enough, but remember, seven of the top ten drugs in 2018 were antibody treatments. The field is booming, and AbCellera’s niche could still pay off.\nHostA: We’ll see. For now, I’m keeping my expectations low."
}